ReviewActa neurologica Belgica2021
Is there a common pathophysiological mechanism between COVID-19 and depression?
Review in Acta neurologica Belgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Cytokine Blockade Attenuates Inflammation and Improves Depressive Psychopathology After COVID-19: A Naturalistic Observational Study.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Observational
- Caspases and brain-derived Neurotrophic Factor Levels and their Correlations with Psychiatric Symptoms in post-COVID-19.Neurotoxicity research · 2025Article
- Increased risk of depression and anxiety in patients with chronic back pain following COVID-19 infection based on a nationwide population-based study.Scientific reports · 2025Article
- Mood symptoms, cognitive function, and changes of brain hemodynamics in patients with COVID-19: A functional near-infrared spectroscopy study.World journal of psychiatry · 2025Article
- Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.Life (Basel, Switzerland) · 2025Review
- Molecular insights into the bidirectional link between anxiety and COVID-19: a combined clinical and bioinformatics approach.Frontiers in psychiatry · 2025Article
- Identifying key biomarkers and therapeutic candidates for post-COVID-19 depression through integrated omics and bioinformatics approaches.Translational neuroscience · 2024Article
- Long COVID, the Brain, Nerves, and Cognitive Function.Neurology international · 2023Review
- Stress levels, psychological symptoms, and C-reactive protein levels in COVID-19: A cross-sectional study.Journal of affective disorders · 2023Article
- Depressive and anxiety symptoms in adults during the COVID-19 pandemic in England: A panel data analysis over 2 years.PLoS medicine · 2023Article
- Registered nurses' management of depression in general wards.Health SA = SA Gesondheid · 2023Article
- Cognitive inhibition deficit in long COVID-19: An exploratory study.Frontiers in neurology · 2023Article
- The Relationship Between COVID-19 and the Development of Depression: Implications on Mental Health.Neuroscience insights · 2023Review
- Reactive gliosis and neuroinflammation: prime suspects in the pathophysiology of post-acute neuroCOVID-19 syndrome.Frontiers in neurology · 2023Review
- Psychosis and Bilateral Peripheral Facial Palsy Associated With COVID-19.Journal of medical cases · 2022Article
- The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences.Pharmaceutics · 2022Review
- The Relationship between Mental Disorders and the COVID-19 Pandemic-Course, Risk Factors, and Potential Consequences.International journal of environmental research and public health · 2022Review
- Mapping the structure of depression biomarker research: A bibliometric analysis.Frontiers in psychiatry · 2022Article
- Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution.Frontiers in psychiatry · 2022Article
- Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a disease caused by SARS-CoV-2 and was initially considered to cause serious damage to the respiratory system. Over time, it has been found to affect other organs due to its ability to bind to the ACE2 receptor (type 2 angiotensin-converting enzyme), which can be found in various tissues, including the central nervous system. In addition, a large formation of pro-inflammatory cytokines responsible for various lesions was observed during the evolution of this disease. Our objective was to demonstrate the molecular mechanisms involved in the infection that may demonstrate the relationship between COVID-19 and the development of depressive conditions. Based on the main medical databases (LiLacs, SciELO, Bireme, Scopus, EBSCO, and PubMed) and using the terms 'coronavirus infections' AND 'Inflammation' AND 'depression' AND 'cytokines', we conducted an integrative review of articles published in 2020. Considering this stage of Covid-19 and the inflammatory component of depression, this review showed a relationship between these two conditions based on common pathophysiological mechanisms indicating possible depressive disorders in surviving patients, especially in the most severe cases. The role of inflammatory cytokines and the presence of ACE-2 receptors on the cell surface appear to be the common pathophysiological mechanism between COVID-19 and depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.